TCOV
NVCT icon

Trust Company of Vermont’s Nuvectis Pharma NVCT Stock Holding History

Trust Company of Vermont’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$4.1K – 928
2024
Q1 		$4.1K Buy
+500
New +$4.25K ﹤0.01% 752

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Trust Company of Vermont's NVCT Position: Q2 2024 in Review

Trust Company of Vermont sold out of Nuvectis Pharma (NVCT) in Q2 2024, closing a stake of 500 shares — an estimated $4.1K sold.

Trust Company of Vermont first reported a position in NVCT in Q1 2024 and held it in 1 quarter. The position peaked at $4.1K in Q1 2024. 41 funds tracked by Wall St. Rank hold NVCT as of Q2 2024.

  • Trust Company of Vermont reported no remaining Nuvectis Pharma position as of Q2 2024 after selling out during the quarter.
  • Trust Company of Vermont sold 500 Nuvectis Pharma shares in Q2 2024, an estimated $4.1K.
  • Trust Company of Vermont first reported a position in Nuvectis Pharma in Q1 2024 and held it in 1 quarter.
  • Trust Company of Vermont's Nuvectis Pharma position peaked at $4.1K in Q1 2024.
  • 41 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2024.

Based on Trust Company of Vermont's 13F filing for Q2 2024, filed 9 Jul 2024.